Cryoablation Offers Long-Term RCC Control
The 5-year disease-free and cancer-specific survival rates were 94.7% and 100%, respectively.
STOCKHOLM—Laparoscopic renal cryoablation of small renal cell carcinoma (RCC) tumors offers optimal and durable cancer control, study findings presented at the European Association of Urology 29th annual congress suggest.
In a single-institution study of 189 patients with a median follow-up of 55 months (range 1-156 months), Alessandro Larcher, MD, of Vita-Salute San Raffaele University in Milano, and colleagues found that the procedure is associated with 5-year disease-free, cancer-specific, and overall survival rates of 94.7%, 100%, and 94.5%, respectively, in patients with RCC.
The study population had a median tumor size of 21 mm (range 7-40 mm). The mean ice-ball diameter after surgery was 44.8 mm (range 18-80 mm), and it decreased over time. Histologic examination revealed 118 RCC tumors, 77 benign lesions, and 20 non-diagnostic specimens.
The median time to disease recurrence was 18 months (range 6-48 months).